Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Hims & Hers Health has an accrual ratio of -0.32 for the year to September 2024.

highlighting brands like HIMS. “During [the pandemic] you had a heightened awareness of wellness,” said Marie Driscoll, a ...

EchoStor Technologies, a leading technology solutions provider, today announced that CRN, a brand of The Channel Company, has named EchoStor a 2024 Triple Crown Award winner. This elite recognition is ...

IntelePeer, a leading AI-powered Communications Automation provider, has today announced the availability of its SmartAgent and SmartOffice solutions, powered by the latest in generative AI technology ...

Teladoc Health (NYSE: TDOC) has struggled to navigate a shifting landscape in the virtual care industry. At the time of ...

ICD is investing EUR 40 million for the construction and operation of a 630-bed multidisciplinary hospital in the city of ...

Buy HIMS near 22.19 target 27.44 stop loss @ 22.13 Details The technical summary data tells us to buy HIMS near 22.19 with an ...

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access branded GLP-1 ...

Forget the CVS detour, the small talk with the pharmacist, and the uncomfortable insurance dance. Welcome to online ...

In recent trading activity, Hims & Hers Health, Inc.'s (NYSE:HIMS) Chief Legal Officer, Boughton Soleil, sold shares of the company's Class A Common Stock. The transaction,... Andrew Dudum ...

View the full release here: "Marketers often struggle aligning affiliate data with attribution platforms, like Adobe Experience Cloud," said Stephanie Harris, founder & CEO of PrtnerCentric. "Our ...